Chipscreen Biosciences’ Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

SHENZHEN, China, July 31, 2025 /PRNewswire/ — Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”) announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug…